Best Practices Interacting with Boards Throughout the Biotech Lifecycle

Dr Barbara Wirostko is the Chief Medical Officer and Co-Founder of Qlaris Bio. Dr Wirostko is a practicing glaucoma specialist and is also a Clinical Adjunct Professor at the University of Utah, Moran Eye Center. She was previously the Chief Medical Officer of EyeGate Pharmaceuticals following its acquisition of Jade Therapeutics where Dr Wirostko was Co-Founder and Chief Scientific Officer spearheading the development of the Ocular Bandage Gel for human use. Prior to Jade, she served as the Chief Medical Officer of Altheos, a glaucoma company, and held leadership positions in medical and clinical development at Pfizer in Ophthalmology.Dr Wirostko received her MD from and completed her residency at Columbia University and holds a BA in Microbiology from Cornell University.

Dr. Yan Moore joined Omega Therapeutics as Chief Medical Officer and brings deep experience in clinical drug development. Prior to Omega, he served as Senior Vice President, Head of Oncology Therapeutic Area at Ipsen Pharmaceuticals, and before that as Chief Medical Officer and Senior Vice President of Clinical Development and Research and Development at Anchiano Therapeutics (previously BioCanCell Therapeutics).In these roles, Dr. Moore was responsible for identifying and executing research and development objectives in areas of oncology and immune-modulatory therapies, managing clinical and preclinical drug development (pre-IND to Phase 1), scientific and development strategy, creation of internal drug development engines to support the overall portfolio strategies and managing global medical affairs strategy. Previously, Dr. Moore held several senior roles of increasing responsibility at Ariad Pharmaceuticals, Sanofi Oncology, GlaxoSmithKline, and Bristol-Myers Squibb, among others. As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.Dr. Moore has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Moore received his medical degree and Bachelor of Medical Sciences from the Sackler School of Medicine at Tel Aviv University, MBA from the LeBow College of Business at Drexel University and completed the Advanced Management Program at Harvard Business School.

Dr. Randall Kaye has over 30 years of experience in the medical field and has served as Chief Medical Officer since March 2022. Prior to joining Longboard, Dr. Kaye was Chief Medical Officer of Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions.  He previously served as Chief Medical Officer of Click Therapeutics, Inc., a leader in digital healthcare innovation, where he was involved in the development of software as a prescription medical treatment for a number of chronic debilitating conditions. Prior to Click, he served as Chief Scientific Officer of SSI Strategy Holdings LLC, where he oversaw clinical development, medical affairs and pharmacovigilance. In conjunction with his role at SSI Strategy, he was Chief Medical Officer of Axsome Therapeutics, Inc. Earlier in his career, Dr. Kaye held the positions of Chief Medical Officer of Avanir Pharmaceuticals, Inc. (acquired by Otsuka Pharmaceutical Co.) and Vice President, Medical Affairs of Scios Inc. (acquired by Johnson & Johnson) and InterMune, Inc. (acquired by Roche Holding AG). He also held clinical development and medical affairs positions at Pfizer Inc. Dr. Kaye earned an M.D., M.P.H. and B.S. at George Washington University, completed his pediatric training at UMASS Medical Center and finished his academic training as a postdoctoral Research Fellow at Harvard Medical School.